Peritoneovenous shunt occlusion. Etiology, diagnosis, therapy.
Electronic pressure testing of every LeVeen valve has practically eliminated mechanical malfunction as a cause of shunt failure. Nonetheless, failures do occur and in a series of 240 cases, early or late shunt failure occurred in 29 patients. Thirty-five additional cases of failures were either referred by other physicians over a period of 6 years or information and x-rays were accumulated by direct contact. Shunt failure becomes manifest by a sudden reaccumulation of ascites in patients with a previously functioning shunt. In immediate failure, the ascites may fail to disappear after surgery or reaccumulate if removed. Ideally, caval clotting should be first excluded by x-ray visualization of the superior vena prior to injection of the shunt with contrast agent. Shuntograms are done with fine-bore needles. The venous pressure is also measured. The entry of contrast into the vena cava without pooling indicates a patent venous limb. The contrast will empty from the venous tubing with forceful inspiration if the entire system is patent. The venous tube will not clear if the valve or peritoneal collecting tubes are blocked. Only the valve and collecting tube need then be replaced if contrast enters the cava but does not leave the venous tubing. Occluded valves must not be flushed to restore patency since inflammatory exudate and cellular debris are erroneously identified as "fibrin flecks." Histology and culture are mandatory. Immediate and early failure are often caused by malposition of the venous tubing. Malplacements can often be diagnosed simply by chest x-rays. Intraoperative injection of methylene blue into the venous tubing establishes a satisfactory washout prior to wound closure. Fresh clots in the vena cava can be dissolved by the slow injection of streptokinase into the venous tubing. Other patent veins are chosen for access. Patients having repeat surgery after clotting must be heparinized to prevent a similar recurrence. Flushing blood clots from the cava can be fatal.
D001201:Ascites / Q000503:physiopathology; D004868:Equipment Failure; D006331:Heart Diseases / Q000503:physiopathology; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007430:Intraoperative Care; D010536:Peritoneovenous Shunt / Q000009:adverse effects*; D011182:Postoperative Care; D011856:Radiographic Image Enhancement; D013902:Radiography, Thoracic; D012086:Reoperation; D013300:Streptokinase / Q000627:therapeutic use; D013927:Thrombosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology; D014656:Vascular Surgical Procedures / Q000009:adverse effects*; D014683:Vena Cava, Superior / Q000000981:diagnostic imaging
D006493:Heparin; D013300:Streptokinase